Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and delayed rituximab with ibrutinib consolidation in treatment‑naïve CLL
2024-514687-33-00Phase 2Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, rituximab and ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Undetectable minimal residual disease in bone marrow. Planned start Aug 2024; status: authorised.
02
Drugs
venetoclaxrituximabibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-514687-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514687-33-00.